
EquityIndex FundsVery High Risk
Regular
NAV (03-Dec-25)
Returns (Since Inception)
Fund Size
₹168 Cr
Expense Ratio
1.06%
ISIN
INF754K01LR3
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+7.05%
— (Cat Avg.)
3 Years
+18.18%
— (Cat Avg.)
5 Years
+14.38%
— (Cat Avg.)
Since Inception
+15.61%
— (Cat Avg.)
| Equity | ₹167.66 Cr | 99.89% |
| Others | ₹0.18 Cr | 0.11% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹18.74 Cr | 11.16% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.31 Cr | 6.14% |
| Cipla Ltd | Equity | ₹9.8 Cr | 5.84% |
| Eli Lilly and Co | Equity | ₹9.65 Cr | 5.75% |
| Divi's Laboratories Ltd | Equity | ₹9.3 Cr | 5.54% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.93 Cr | 5.32% |
| Dr Reddy's Laboratories Ltd | Equity | ₹8.08 Cr | 4.81% |
| Johnson & Johnson | Equity | ₹6.3 Cr | 3.75% |
| Fortis Healthcare Ltd | Equity | ₹5.8 Cr | 3.45% |
| AbbVie Inc | Equity | ₹5.34 Cr | 3.18% |
| Lupin Ltd | Equity | ₹5.18 Cr | 3.08% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.87 Cr | 2.90% |
| Laurus Labs Ltd | Equity | ₹3.86 Cr | 2.30% |
| Aurobindo Pharma Ltd | Equity | ₹3.44 Cr | 2.05% |
| Mankind Pharma Ltd | Equity | ₹3.41 Cr | 2.03% |
| Novartis AG ADR | Equity | ₹3.26 Cr | 1.94% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹3.08 Cr | 1.84% |
| Merck & Co Inc | Equity | ₹2.99 Cr | 1.78% |
| Abbott Laboratories | Equity | ₹2.98 Cr | 1.78% |
| Thermo Fisher Scientific Inc | Equity | ₹2.98 Cr | 1.77% |
| Zydus Lifesciences Ltd | Equity | ₹2.83 Cr | 1.69% |
| Alkem Laboratories Ltd | Equity | ₹2.66 Cr | 1.59% |
| Intuitive Surgical Inc | Equity | ₹2.66 Cr | 1.58% |
| Biocon Ltd | Equity | ₹2.3 Cr | 1.37% |
| Amgen Inc | Equity | ₹2.23 Cr | 1.33% |
| Novo Nordisk AS ADR | Equity | ₹2.2 Cr | 1.31% |
| Gilead Sciences Inc | Equity | ₹2.07 Cr | 1.23% |
| Ipca Laboratories Ltd | Equity | ₹2.05 Cr | 1.22% |
| Danaher Corp | Equity | ₹1.92 Cr | 1.15% |
| Stryker Corp | Equity | ₹1.7 Cr | 1.01% |
| Gland Pharma Ltd | Equity | ₹1.65 Cr | 0.98% |
| Medtronic PLC | Equity | ₹1.61 Cr | 0.96% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.52 Cr | 0.90% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.45 Cr | 0.86% |
| Piramal Pharma Ltd | Equity | ₹1.38 Cr | 0.82% |
| Syngene International Ltd | Equity | ₹1.36 Cr | 0.81% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.28 Cr | 0.76% |
| Ajanta Pharma Ltd | Equity | ₹1.24 Cr | 0.74% |
| Global Health Ltd | Equity | ₹1.22 Cr | 0.73% |
| Cohance Lifesciences Ltd | Equity | ₹1 Cr | 0.59% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.97 Cr | 0.58% |
| Becton Dickinson & Co | Equity | ₹0.71 Cr | 0.42% |
| Agilent Technologies Inc | Equity | ₹0.58 Cr | 0.34% |
| IQVIA Holdings Inc | Equity | ₹0.52 Cr | 0.31% |
| Illumina Inc | Equity | ₹0.27 Cr | 0.16% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.26 Cr | 0.15% |
| Net Receivables/(Payables) | Cash - Repurchase Agreement | ₹-0.08 Cr | 0.05% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
48.52%
Mid Cap Stocks
16.91%
Small Cap Stocks
3.21%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹167.66 Cr | 99.89% |
Standard Deviation
This fund
12.46%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.92
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021

Since February 2021
ISIN INF754K01LR3 | Expense Ratio 1.06% | Exit Load No Charges | Fund Size ₹168 Cr | Age 5 years 1 month | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,00,953 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk


EquityIndex FundsVery High Risk
Regular
NAV (03-Dec-25)
Returns (Since Inception)
Fund Size
₹168 Cr
Expense Ratio
1.06%
ISIN
INF754K01LR3
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+7.05%
— (Cat Avg.)
3 Years
+18.18%
— (Cat Avg.)
5 Years
+14.38%
— (Cat Avg.)
Since Inception
+15.61%
— (Cat Avg.)
| Equity | ₹167.66 Cr | 99.89% |
| Others | ₹0.18 Cr | 0.11% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹18.74 Cr | 11.16% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.31 Cr | 6.14% |
| Cipla Ltd | Equity | ₹9.8 Cr | 5.84% |
| Eli Lilly and Co | Equity | ₹9.65 Cr | 5.75% |
| Divi's Laboratories Ltd | Equity | ₹9.3 Cr | 5.54% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.93 Cr | 5.32% |
| Dr Reddy's Laboratories Ltd | Equity | ₹8.08 Cr | 4.81% |
| Johnson & Johnson | Equity | ₹6.3 Cr | 3.75% |
| Fortis Healthcare Ltd | Equity | ₹5.8 Cr | 3.45% |
| AbbVie Inc | Equity | ₹5.34 Cr | 3.18% |
| Lupin Ltd | Equity | ₹5.18 Cr | 3.08% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.87 Cr | 2.90% |
| Laurus Labs Ltd | Equity | ₹3.86 Cr | 2.30% |
| Aurobindo Pharma Ltd | Equity | ₹3.44 Cr | 2.05% |
| Mankind Pharma Ltd | Equity | ₹3.41 Cr | 2.03% |
| Novartis AG ADR | Equity | ₹3.26 Cr | 1.94% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹3.08 Cr | 1.84% |
| Merck & Co Inc | Equity | ₹2.99 Cr | 1.78% |
| Abbott Laboratories | Equity | ₹2.98 Cr | 1.78% |
| Thermo Fisher Scientific Inc | Equity | ₹2.98 Cr | 1.77% |
| Zydus Lifesciences Ltd | Equity | ₹2.83 Cr | 1.69% |
| Alkem Laboratories Ltd | Equity | ₹2.66 Cr | 1.59% |
| Intuitive Surgical Inc | Equity | ₹2.66 Cr | 1.58% |
| Biocon Ltd | Equity | ₹2.3 Cr | 1.37% |
| Amgen Inc | Equity | ₹2.23 Cr | 1.33% |
| Novo Nordisk AS ADR | Equity | ₹2.2 Cr | 1.31% |
| Gilead Sciences Inc | Equity | ₹2.07 Cr | 1.23% |
| Ipca Laboratories Ltd | Equity | ₹2.05 Cr | 1.22% |
| Danaher Corp | Equity | ₹1.92 Cr | 1.15% |
| Stryker Corp | Equity | ₹1.7 Cr | 1.01% |
| Gland Pharma Ltd | Equity | ₹1.65 Cr | 0.98% |
| Medtronic PLC | Equity | ₹1.61 Cr | 0.96% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.52 Cr | 0.90% |
| Narayana Hrudayalaya Ltd | Equity | ₹1.45 Cr | 0.86% |
| Piramal Pharma Ltd | Equity | ₹1.38 Cr | 0.82% |
| Syngene International Ltd | Equity | ₹1.36 Cr | 0.81% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.28 Cr | 0.76% |
| Ajanta Pharma Ltd | Equity | ₹1.24 Cr | 0.74% |
| Global Health Ltd | Equity | ₹1.22 Cr | 0.73% |
| Cohance Lifesciences Ltd | Equity | ₹1 Cr | 0.59% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.97 Cr | 0.58% |
| Becton Dickinson & Co | Equity | ₹0.71 Cr | 0.42% |
| Agilent Technologies Inc | Equity | ₹0.58 Cr | 0.34% |
| IQVIA Holdings Inc | Equity | ₹0.52 Cr | 0.31% |
| Illumina Inc | Equity | ₹0.27 Cr | 0.16% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.26 Cr | 0.15% |
| Net Receivables/(Payables) | Cash - Repurchase Agreement | ₹-0.08 Cr | 0.05% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
48.52%
Mid Cap Stocks
16.91%
Small Cap Stocks
3.21%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹167.66 Cr | 99.89% |
Standard Deviation
This fund
12.46%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.92
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021

Since February 2021
ISIN INF754K01LR3 | Expense Ratio 1.06% | Exit Load No Charges | Fund Size ₹168 Cr | Age 5 years 1 month | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,00,953 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments